-- 加拿大皇家银行资本市场（RBC Capital Markets）在周五发布的一份客户报告中指出，艾伯维（AbbVie，股票代码：ABBV）预计第一季度盈利将符合预期，但这可能不足以提振市场对这家制药公司的信心。 该券商预计艾伯维第一季度每股收益为2.59美元，而FactSet目前的共识预期为非GAAP每股收益2.83美元。 今年4月初，艾伯维将第一季度调整后每股收益预期下调至2.56美元至2.60美元。该公司表示，预计与收购在研研发项目及其他费用相关的7.44亿美元税前支出将对其每股收益产生0.41美元的负面影响。 加拿大皇家银行分析师Trung Huynh在报告中写道：“我们认为市场对艾伯维的预期很高，即使业绩符合预期，也可能不足以扭转市场负面情绪。” “除非公司业绩明显超出预期，否则我们预计目前的低迷状态将持续到（2026年第二季度）。” 艾伯维计划于4月29日发布最新季度业绩。 据加拿大皇家银行（RBC）称，该公司免疫药物Skyrizi和Rinvoq第一季度的销售额与市场预期和指引相符。该券商预计，受《通胀减排法案》价格侵蚀和抗癌药物Imbruvica销量下降的影响，艾伯维的肿瘤业务将出现“小幅”同比下滑。 加拿大皇家银行预测该公司营收将达到148.2亿美元，而华尔街的预期为147.3亿美元。 该券商维持对艾伯维股票的“跑赢大盘”评级，目标价为260美元。
Related Articles
Equities
Petro Rabigh Emerges From Loss in Q1; Revenue Grows
Rabigh Refining and Petrochemical (SASE:2380), d/b/a Petro Rabigh, said Sunday it swung back to profit in the first quarter of 2026, while revenue increased year over year.Net profit attributable to shareholders of the issuer for the three months ended March 31 was 1.47 billion Saudi riyals, compared with the attributable loss of 691 million riyals earlier. EPS moved to 0.88 riyal from a loss per share of 0.41 riyal.The Tadawul-listed oil refining and petrochemical company's revenue was 14.85 billion riyals, compared with 11.21 billion riyals a year ago.
$SASE:2380
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.
$HIG
Research
Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.
$BKR